Overview of Anti-Obesity Medications for Weight Management
Keywords:
Obesity, medications, lifestyle, semaglutide
Abstract
Obesity is an increasingly prevalent disease across the globe. Lifestyle modification though a cornerstone in management falls short of goal many times and hence the need for pharmacotherapy for Obesity. There have been many on and off label used medications and some medications have also been withdrawn from the market. However, the future looks exciting with many new treatments on the horizon. Current communication tries to look at existing and future possibilities in obesity treatment armamentarium.
References
1. Obesity and overweight [Internet]. World Health Organization. World Health Organization; [cited 2021 Jun 28]. Available from: https://www.who.int/news-room/factsheets/ detail/obesity-and-overweight .
2. Noncommunicable diseases: Risk factors [Internet]. World Health Organization. World Health Organization; [cited 2021Jun 28]. Available from: https://www.who.int/gho/ncd/risk_ factors/overweight_obesity/obesity_adults/en
3. Ahirwar R, Mondal RP., Prevalence of obesity in India: A systematic review. Diabetes Metab Syndr Jan-Feb 2019;13(1):318- 321
4. Bray GA, Kim KK, Wilding JPH. Obesity: a chronic relapsing progressive disease process. A position statement of the World Obesity Federation. Obes Rev. 2017; 18:715-723.
5. Schwartz MW, Seeley RJ, Zeltser LM, et al. Obesity pathogenesis: An Endocrine Society scientific statement. Endocr Rev. 2017; 38:267-296.
6. Heymsfield SB, Wadden TA. Mechanisms, pathophysiology, and management of obesity. N Engl J Med. 2017; 376:254-266.
7. Agborsangaya CB, Majumdar SR, Sharma AM, Gregg EW, Padwal RS. Multimorbidity in a prospective cohort: prevalence and associations with weight loss and health status in severely obese patients. Obesity (Silver Spring). 2015; 23:707- 712.
8. Dengo AL, Dennis EA, Orr JS, et al. Arterial destiffening with weight loss in overweight and obese middle-aged and older adults. Hypertension. 2010; 55:855-861.
9. Cefalu WT, Bray GA, Home PD, et al. Advances in the science, treatment, and prevention of the disease of obesity: reflections from a Diabetes Care editors’ expert forum. Diabetes Care. 2015; 38:1567-1582.
10. Yumuk V, Tsigos C, Fried M, et al. European guidelines for obesity management in adults. Obes Facts. 2015; 8:402-424. 11. Jensen MD, Ryan DH, Apovian CM, et al. 2013 AHA/ACC/ TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines and The Obesity Society. J Am Coll Cardiol. 2014; 63:2985-3023.
12. Apovian CM, Aronne LJ, Bessesen DH, et al. Pharmacological management of obesity: an endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2015; 100:342-362.
13. Durrer Schutz D, Busetto L, Dicker D, et al. European Practical and Patient-Centred Guidelines for Adult Obesity Management in Primary Care. Obes Facts. 2019; 12:40-66.
14. Adipex-P® (phentermine hydrochloride) [FDA: prescribing information]. Horsham, PA: Teva; Apr 2012.
15. Xenical® (orlistat) [FDA: prescribing information]. South San Francisco, CA: Genentech; Aug 2015.
16. Alli® (orlistat) [FDA: prescribing information]. Warren, NJ: GlaxoSmithKline May 2017.
17. Qsymia® (phentermine and topiramate extended-release) [FDA: prescribing information]. Campbell, CA: Vivus; Mar 2018.
18. Contrave® (naltrexone hydrochloride and bupropion hydrochloride) [FDA: prescribing information]. La Jolla, CA: Orexigen; Jun 2018.
19. Saxenda® (liraglutide 3.0 mg) [FDA: prescribing information]. Plainsboro, NJ: Novo Nordisk; Oct 2018.
20. Mysimba® (naltrexone hydrochloride and bupropion hydrochloride) [EMA: EPAR - product information]. Ireland:Orexigen; Jun 2017.
21. Mann T, Tomiyama AJ, Westling E, Lew AM, Samuels B, Chatman J. Medicare’s search for effective obesity treatments: diets are not the answer. Am Psychol. 2007; 62:220- 233.
22. FDA Approves ‘Game Changer’ Semaglutide for Weight Loss [Internet]. Medscape. 2021 [cited 2021 Jun 28]. Available from: https://www.medscape.com/viewarticle/952441.
2. Noncommunicable diseases: Risk factors [Internet]. World Health Organization. World Health Organization; [cited 2021Jun 28]. Available from: https://www.who.int/gho/ncd/risk_ factors/overweight_obesity/obesity_adults/en
3. Ahirwar R, Mondal RP., Prevalence of obesity in India: A systematic review. Diabetes Metab Syndr Jan-Feb 2019;13(1):318- 321
4. Bray GA, Kim KK, Wilding JPH. Obesity: a chronic relapsing progressive disease process. A position statement of the World Obesity Federation. Obes Rev. 2017; 18:715-723.
5. Schwartz MW, Seeley RJ, Zeltser LM, et al. Obesity pathogenesis: An Endocrine Society scientific statement. Endocr Rev. 2017; 38:267-296.
6. Heymsfield SB, Wadden TA. Mechanisms, pathophysiology, and management of obesity. N Engl J Med. 2017; 376:254-266.
7. Agborsangaya CB, Majumdar SR, Sharma AM, Gregg EW, Padwal RS. Multimorbidity in a prospective cohort: prevalence and associations with weight loss and health status in severely obese patients. Obesity (Silver Spring). 2015; 23:707- 712.
8. Dengo AL, Dennis EA, Orr JS, et al. Arterial destiffening with weight loss in overweight and obese middle-aged and older adults. Hypertension. 2010; 55:855-861.
9. Cefalu WT, Bray GA, Home PD, et al. Advances in the science, treatment, and prevention of the disease of obesity: reflections from a Diabetes Care editors’ expert forum. Diabetes Care. 2015; 38:1567-1582.
10. Yumuk V, Tsigos C, Fried M, et al. European guidelines for obesity management in adults. Obes Facts. 2015; 8:402-424. 11. Jensen MD, Ryan DH, Apovian CM, et al. 2013 AHA/ACC/ TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines and The Obesity Society. J Am Coll Cardiol. 2014; 63:2985-3023.
12. Apovian CM, Aronne LJ, Bessesen DH, et al. Pharmacological management of obesity: an endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2015; 100:342-362.
13. Durrer Schutz D, Busetto L, Dicker D, et al. European Practical and Patient-Centred Guidelines for Adult Obesity Management in Primary Care. Obes Facts. 2019; 12:40-66.
14. Adipex-P® (phentermine hydrochloride) [FDA: prescribing information]. Horsham, PA: Teva; Apr 2012.
15. Xenical® (orlistat) [FDA: prescribing information]. South San Francisco, CA: Genentech; Aug 2015.
16. Alli® (orlistat) [FDA: prescribing information]. Warren, NJ: GlaxoSmithKline May 2017.
17. Qsymia® (phentermine and topiramate extended-release) [FDA: prescribing information]. Campbell, CA: Vivus; Mar 2018.
18. Contrave® (naltrexone hydrochloride and bupropion hydrochloride) [FDA: prescribing information]. La Jolla, CA: Orexigen; Jun 2018.
19. Saxenda® (liraglutide 3.0 mg) [FDA: prescribing information]. Plainsboro, NJ: Novo Nordisk; Oct 2018.
20. Mysimba® (naltrexone hydrochloride and bupropion hydrochloride) [EMA: EPAR - product information]. Ireland:Orexigen; Jun 2017.
21. Mann T, Tomiyama AJ, Westling E, Lew AM, Samuels B, Chatman J. Medicare’s search for effective obesity treatments: diets are not the answer. Am Psychol. 2007; 62:220- 233.
22. FDA Approves ‘Game Changer’ Semaglutide for Weight Loss [Internet]. Medscape. 2021 [cited 2021 Jun 28]. Available from: https://www.medscape.com/viewarticle/952441.
Published
2021-07-24
How to Cite
Dr. Ameya Joshi, Dr. Chandni Seth. (2021). Overview of Anti-Obesity Medications for Weight Management. The Indian Practitioner, 74(7), 29-32. Retrieved from http://articles.theindianpractitioner.com/index.php/tip/article/view/1215
Section
Clinical Practice
